Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: OABI

OmniAb, Inc.

Healthcare | Biotechnology

No licensed closing price on file for OABI. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-0.46

OmniAb, Inc. (NASDAQ: OABI) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 17:54 UTC.

What OmniAb, Inc. does

OmniAb licenses antibody discovery technology to pharmaceutical, biotech, and academic partners to help identify therapeutic antibodies. The company's platform uses genetically engineered transgenic animals, including OmniRat, OmniChicken, and OmniMouse, combined with computational tools and screening methods to discover fully human antibodies with optimal characteristics. OmniAb generates revenue through platform license agreements that include upfront fees, annual access fees, service revenue, milestone payments, and royalties on commercial sales.

Summarized from OmniAb, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-0.46

Revenue, margins & earnings

FY2021: net loss $27M on revenue $35M$35MFY2021FY2022: net loss $22M on revenue $59M$59MFY2022FY2023: net loss $51M on revenue $34M$34MFY2023FY2024: net loss $62M on revenue $26M$26MFY2024FY2025: net loss $65M on revenue $19M$19MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-08-03
  • 2026-08-03Chief Operating OfficerStock Option (right to buy)Award800,000—
  • 2026-06-18DirectorStock Option (right to buy)Award40,000—
  • 2026-06-18DirectorOption exercise20,000—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does OmniAb, Inc. do?

OmniAb licenses antibody discovery technology to pharmaceutical, biotech, and academic partners to help identify therapeutic antibodies.

When did OABI last file with the SEC?

OmniAb, Inc.'s most recent SEC filing on record is a 8-K filed 2026-07-13. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 17:54 UTC. This page is also available as JSON at /api/data?ticker=OABI and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for OABI and 5,000+ tickers.

Create a free account — keep OABI
For your agent
GET /api/data?ticker=OABI

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt